Transactions of Managers and Closely Associated Persons
Rhea-AI Summary
Alvotech (ALVO) disclosed filings to the Luxembourg CSSF showing a single share transfer within the Aztiq group: 2,701,617 shares were sold and acquired on January 30, 2026 at USD 4.74 per share. The notices reflect an intra‑group transfer between ATP Holdings ehf. and Aztiq Pharma Partners S.à r.l.
Contact provided: Benedikt Stefansson, VP investor relations, valvotech.ir@alvotech.com.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Peer stocks in Healthcare/Drug Manufacturers - Specialty & Generic show mixed one-day moves between -1 and 0.96, suggesting today’s action in ALVO is stock-specific rather than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 11 | Share capital increase | Negative | -6.7% | Issued 12,500,000 new shares to subsidiary to support prior obligations. |
| Feb 05 | Clinical trial results | Positive | -2.0% | Pivotal PK study for AVT80 met all primary endpoints versus Entyvio. |
| Feb 02 | Commercial agreements | Positive | -0.9% | Signed Sandoz supply and commercialization deals for multiple biosimilars. |
| Jan 29 | Settlement agreement | Positive | +2.5% | Global licensing and settlement for Eylea biosimilar enabling staged launches. |
| Jan 07 | Insider transaction correction | Neutral | +1.5% | Corrected CSSF filings for large insider-related share trades in Dec 2025. |
Recent positive operational and clinical news has often coincided with flat-to-negative next-day moves, while technical or clarification notices saw modest positive or negative reactions.
Over recent months, Alvotech has reported several strategically important events, including a global settlement for its Eylea biosimilar, new commercialization agreements, and positive pivotal PK results for AVT80, alongside capital structure moves such as a 12,500,000-share issuance on Feb 11, 2026. It also frequently reports transactions by entities closely associated with management, including large trades in December 2025. Compared with these items, the latest intra-group transfer at USD 4.74 per share primarily extends this pattern of detailed transparency around insider-related dealings.
Market Pulse Summary
This announcement details an internal transfer of 2,701,617 shares at USD 4.74 per share between entities within the Aztiq group, highlighting continued transparency around transactions by managers and closely associated persons. Because the shares moved within the same ownership group, the economic impact on outside shareholders appears limited. Investors following Alvotech may focus more on prior news about capital increases, clinical milestones, and commercialization agreements when assessing the overall equity story.
AI-generated analysis. Not financial advice.
Attached are copies of two filings with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons. ATP Holdings ehf. announced a sale of 2,701,617 shares in Alvotech on January 30, 2026, and Aztiq Pharma Partners S.à r.l. ("Aztiq") announced the acquisition of 2,701,617 shares in Alvotech on January 30, 2026. ATP Holdings ehf. belongs to the Aztiq group and the transaction was thus a transfer of shares within the group. The announcements related to the same transaction and the transaction price was USD 4.74 per share.
ALVOTECH INVESTOR RELATIONS
Benedikt Stefansson, VP
alvotech.ir@alvotech.com
Attachments
FAQ
What transaction did ALVO disclose on February 26, 2026?
Does the ALVO filing show a market sale or intra‑group transfer?
How many ALVO shares changed hands and at what price on January 30, 2026?
Which parties were involved in the ALVO managers' transaction notices?
Where can investors direct inquiries about the ALVO transaction disclosure?
